ATE397932T1 - Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien - Google Patents
Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmienInfo
- Publication number
- ATE397932T1 ATE397932T1 AT03723907T AT03723907T ATE397932T1 AT E397932 T1 ATE397932 T1 AT E397932T1 AT 03723907 T AT03723907 T AT 03723907T AT 03723907 T AT03723907 T AT 03723907T AT E397932 T1 ATE397932 T1 AT E397932T1
- Authority
- AT
- Austria
- Prior art keywords
- ranolazine
- arrhythmia
- medication
- treatment
- production
- Prior art date
Links
- 206010003119 arrhythmia Diseases 0.000 title abstract 2
- 230000006793 arrhythmia Effects 0.000 title abstract 2
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229960000213 ranolazine Drugs 0.000 title 1
- 208000018452 Torsade de pointes Diseases 0.000 abstract 2
- 208000002363 Torsades de Pointes Diseases 0.000 abstract 2
- 208000001871 Tachycardia Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000031352 familial ventricular tachycardia Diseases 0.000 abstract 1
- 208000012404 paroxysmal familial ventricular fibrillation Diseases 0.000 abstract 1
- 230000006794 tachycardia Effects 0.000 abstract 1
- 206010047302 ventricular tachycardia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37015002P | 2002-04-04 | 2002-04-04 | |
| US40829202P | 2002-09-05 | 2002-09-05 | |
| US42258902P | 2002-10-30 | 2002-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397932T1 true ATE397932T1 (de) | 2008-07-15 |
Family
ID=29255318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03723907T ATE397932T1 (de) | 2002-04-04 | 2003-04-04 | Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien |
| AT08004276T ATE470445T1 (de) | 2002-04-04 | 2003-04-04 | Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08004276T ATE470445T1 (de) | 2002-04-04 | 2003-04-04 | Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20030220344A1 (enExample) |
| EP (3) | EP1930007B1 (enExample) |
| JP (1) | JP4608217B2 (enExample) |
| KR (2) | KR20100119804A (enExample) |
| CN (2) | CN101843619A (enExample) |
| AT (2) | ATE397932T1 (enExample) |
| AU (3) | AU2003230810B2 (enExample) |
| CA (1) | CA2481192C (enExample) |
| CY (1) | CY1110400T1 (enExample) |
| DE (2) | DE60332975D1 (enExample) |
| DK (2) | DK1930007T3 (enExample) |
| ES (2) | ES2345573T3 (enExample) |
| IL (1) | IL197406A0 (enExample) |
| MX (1) | MXPA04009637A (enExample) |
| NO (1) | NO330953B1 (enExample) |
| NZ (1) | NZ535610A (enExample) |
| PT (2) | PT1490066E (enExample) |
| SI (2) | SI1930007T1 (enExample) |
| WO (1) | WO2003086401A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| US20040063717A1 (en) * | 2002-05-21 | 2004-04-01 | Andrew Wolff | Method of treating diabetes |
| WO2005061470A1 (en) * | 2003-12-18 | 2005-07-07 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| SG156681A1 (en) * | 2004-11-09 | 2009-11-26 | Cv Therapeutics Inc | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
| KR20070093988A (ko) * | 2005-01-06 | 2007-09-19 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 라놀라진 함유 서방성 약제학적 제형물 |
| US20060263427A1 (en) * | 2005-05-03 | 2006-11-23 | Roberts Richard H | Quinine formulations |
| US20080153840A1 (en) * | 2006-12-21 | 2008-06-26 | Luiz Belardinelli | Reduction of cardiovascular symptoms |
| CA2677931A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| CA2678325A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of non-coronary microvascular diseases |
| JP2010518170A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 冠微小血管疾患の処置のためのラノラジンの使用 |
| WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| EA200971073A1 (ru) * | 2007-05-31 | 2010-08-30 | Джилид Пало Альто, Инк. | Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа |
| WO2009100380A1 (en) * | 2008-02-06 | 2009-08-13 | Cv Therapeutics, Inc. | Use of ranolazine for treating pain |
| WO2010028173A2 (en) * | 2008-09-04 | 2010-03-11 | Gilead Palo Alto, Inc. | Method of treating atrial fibrillation |
| WO2010074807A1 (en) * | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| JP2012526848A (ja) * | 2009-05-14 | 2012-11-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｎｓ障害の治療のためのラノラジン |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| CN104350041A (zh) | 2012-05-07 | 2015-02-11 | 塞利克斯比奥私人有限公司 | 用于治疗神经系统疾病的组合物和方法 |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| CA2873093A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| NZ701832A (en) | 2012-05-23 | 2016-08-26 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammatory bowel disease |
| WO2013175377A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| SG11201407322QA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| WO2014027262A2 (en) * | 2012-08-14 | 2014-02-20 | Mahesh Kandula | Compositions and methods for the treatment angina and cardiovascular conditions |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| AU2013311349A1 (en) | 2012-09-08 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| AU2014276346A1 (en) | 2013-06-04 | 2015-12-24 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| CN105611931A (zh) * | 2013-08-01 | 2016-05-25 | 吉利德科学公司 | 治疗长qt综合征的化合物和方法 |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| EP3201168B1 (en) | 2014-09-29 | 2020-03-18 | Cellix Bio Private Limited | Compounds and compositions for the treatment of multiple sclerosis |
| EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| CN110845355A (zh) | 2015-01-06 | 2020-02-28 | 塞尔利克斯生物私人有限公司 | 用于治疗炎症和疼痛的组合物和方法 |
| KR101617683B1 (ko) * | 2015-01-09 | 2016-05-03 | 연세대학교 산학협력단 | 부정맥 치료제 효과 평가 시스템 및 방법 |
| TW201717919A (zh) | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | 雷諾多重壓縮錠劑 |
| WO2018001582A1 (en) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Ranolazine multiple compressed tablets |
| CN116808039A (zh) * | 2023-03-27 | 2023-09-29 | 河南中医药大学第一附属医院 | 青藤碱在制备钾离子、钠离子通道抑制剂中的应用 |
| WO2025010429A1 (en) * | 2023-07-06 | 2025-01-09 | The General Hospital Corporation | Method and apparatus for evaluating cardiac function |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| NZ247044A (en) * | 1989-06-23 | 1997-04-24 | Syntex Usa Inc Substituted For | Use of ranolazine and related piperazine derivatives to treat tissue affected by muscle and neuronal damage, including transplant tissue |
| JPH03141258A (ja) * | 1989-10-25 | 1991-06-17 | Kowa Co | 新規なピペラジン誘導体 |
| ATE211135T1 (de) * | 1993-09-24 | 2002-01-15 | Univ British Columbia | Aminocyclohexylester und ihre anwendung |
| US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| CN1227004C (zh) * | 2000-02-18 | 2005-11-16 | Cv治疗公司 | 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂 |
| US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| WO2001089554A2 (en) * | 2000-05-19 | 2001-11-29 | Bionebraska, Inc. | Treatment of acute coronary syndrome with glp-1 |
| AU2001277938A1 (en) * | 2000-07-21 | 2002-02-05 | Cv Therapeutics, Inc. | Method for treating angina |
| US6573264B1 (en) * | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| US20080109040A1 (en) * | 2002-04-04 | 2008-05-08 | Luiz Belardinelli | Method of treating arrhythmias |
-
2003
- 2003-04-03 US US10/406,894 patent/US20030220344A1/en not_active Abandoned
- 2003-04-04 PT PT03723907T patent/PT1490066E/pt unknown
- 2003-04-04 CA CA2481192A patent/CA2481192C/en not_active Expired - Fee Related
- 2003-04-04 JP JP2003583420A patent/JP4608217B2/ja not_active Expired - Fee Related
- 2003-04-04 DK DK08004276.5T patent/DK1930007T3/da active
- 2003-04-04 CN CN200910171650A patent/CN101843619A/zh active Pending
- 2003-04-04 PT PT08004276T patent/PT1930007E/pt unknown
- 2003-04-04 KR KR1020107021063A patent/KR20100119804A/ko not_active Abandoned
- 2003-04-04 NZ NZ535610A patent/NZ535610A/en not_active IP Right Cessation
- 2003-04-04 DE DE60332975T patent/DE60332975D1/de not_active Expired - Lifetime
- 2003-04-04 KR KR10-2004-7015749A patent/KR20040099395A/ko not_active Ceased
- 2003-04-04 ES ES08004276T patent/ES2345573T3/es not_active Expired - Lifetime
- 2003-04-04 EP EP08004276A patent/EP1930007B1/en not_active Expired - Lifetime
- 2003-04-04 SI SI200331842T patent/SI1930007T1/sl unknown
- 2003-04-04 EP EP10002699A patent/EP2198866A1/en not_active Withdrawn
- 2003-04-04 AU AU2003230810A patent/AU2003230810B2/en not_active Ceased
- 2003-04-04 DK DK03723907T patent/DK1490066T3/da active
- 2003-04-04 DE DE60321550T patent/DE60321550D1/de not_active Expired - Lifetime
- 2003-04-04 EP EP03723907A patent/EP1490066B1/en not_active Expired - Lifetime
- 2003-04-04 AT AT03723907T patent/ATE397932T1/de active
- 2003-04-04 MX MXPA04009637A patent/MXPA04009637A/es active IP Right Grant
- 2003-04-04 AT AT08004276T patent/ATE470445T1/de active
- 2003-04-04 WO PCT/US2003/010434 patent/WO2003086401A1/en not_active Ceased
- 2003-04-04 ES ES03723907T patent/ES2304507T3/es not_active Expired - Lifetime
- 2003-04-04 CN CNB038078716A patent/CN100548300C/zh not_active Expired - Fee Related
- 2003-04-04 SI SI200331293T patent/SI1490066T1/sl unknown
-
2004
- 2004-11-03 NO NO20044783A patent/NO330953B1/no not_active IP Right Cessation
-
2008
- 2008-09-03 CY CY20081100948T patent/CY1110400T1/el unknown
-
2009
- 2009-03-05 IL IL197406A patent/IL197406A0/en unknown
- 2009-03-17 AU AU2009201065A patent/AU2009201065B2/en not_active Ceased
- 2009-09-09 US US12/556,417 patent/US20100004255A1/en not_active Abandoned
-
2011
- 2011-05-09 AU AU2011202135A patent/AU2011202135A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE397932T1 (de) | Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien | |
| ATE517658T1 (de) | Arrythmie-klassifizierung und therapiewahl | |
| DE60010702D1 (de) | Behandlung von titanerz zur herstellung von titandioxidpigmenten | |
| ATE411831T1 (de) | Mehrfach-signalmuster zum filtern von fernfeld-r- zacken | |
| DE69821667D1 (de) | Kardioverter zur Behandlung von Vorhofflattern | |
| EP1803486A3 (en) | Method for discriminating between ventricular and supraventricular arrhythmias | |
| ATE292971T1 (de) | (s,s)-reboxetin zur behandlung von peripheren neuropathien | |
| DE69832842D1 (de) | Herzschrittmacher, Defibrillator und/oder Cardioverter zur Verringerung von Vorhofsarrythmien | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| NO20011283D0 (no) | Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon | |
| CY1106178T1 (el) | 2’- υποκατεστημενα 1,1’-διφαινυλο-2-καρβοξαμιδια, μεθοδος για την παρασκευη τους, η χρηση τους ως φαρμακου καθως και φαρμακευτικα παρασκευασματα που τα πepιεχουν | |
| DE60323994D1 (de) | Verfahren zur herstellung von 2-chlor-1,1,1,2,3,3,3-heptafluorpropan, hexafluorpropen und 1,1,1,2,3,3,3-heptafluorpropan | |
| ATE374619T1 (de) | Verwendung von neurofilamentproteinen zur behandlung von tumoren | |
| DE60214207D1 (de) | Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis | |
| DE602004024526D1 (de) | Kosmetisches peeling-verfahren unter verwendung von harnstoff | |
| DE602004030661D1 (de) | Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis | |
| ATE427363T1 (de) | In kanzerísen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren | |
| ATE380551T1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
| MXPA05011428A (es) | Metodo de tratamiento de fibrilacion atrial o trepidacion auricular. | |
| AU4584100A (en) | Morphinoid compounds | |
| ATE532883T1 (de) | Voc-arme fettungsmittel, ihre verwendung in der herstellung und/oder behandlung von leder und häuten, sowie das ensprechende herstellungs- bzw. behandlungsverfahren | |
| WO2004044144A3 (en) | Methods for inducing regeneration, remyelination, and hypermyelination of nervous tissue | |
| DE60202446D1 (de) | Pharmazeutische formulierung und ihre verwendung für die herstellung eines medikaments zur behandlung von herz-kreislauf-erkrankungen | |
| ATE497784T1 (de) | Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen | |
| ATE127118T1 (de) | 2-alkyl-3-benzoylbenzofurane zur behandlung von herzarrhythmia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1490066 Country of ref document: EP |